a post hoc analysis of SELECT|PsA 1 and 2 trials

a post hoc analysis of SELECT-PsA 1 and 2 trials | Rheumatology

Conclusion. This post hoc analysis expands on the primary analyses of the SELECT-PsA 1 and 2 studies, demonstrating that upadacitinib is ...

A POST-HOC ANALYSIS FROM SELECT-PsA 1

LDA was assessed using MDA (threshold: 5/7 criteria), DAPSA (≤14), PASDAS (≤3.2), and Patient Global Assessment of Disease Activity (PtGA; ≤3).2,3 These post- ...

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

This was a post hoc analysis of the double-blind, placebo-controlled SELECT-PsA 1 (also adalimumab-controlled) and SELECT-PsA 2 trials. Treatment targets ...

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

... Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo ... PsA 1 (also adalimumab-controlled) and SELECT-PsA 2 trials.

WEEK 152 DATA FROM THE SELECT-PSA 1 AND SELECT-PSA 2 ...

Objectives: In this post-hoc analysis, the maintenance of clinical response rates with UPA 15 mg (UPA15) were evaluated through nearly 3 years of treatment ...

Efficacy and safety of upadacitinib in patients with active psoriatic ...

Post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 in patients randomized to ... In this post-hoc analysis of the SELECT-PsA trials, the ...

AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in ...

Post-hoc analyses of the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials show people with active psoriatic arthritis (PsA) demonstrated greater ...

Comparison of Composite Indices for Disease Activity in Patients ...

... A Post-Hoc Analysis from SELECT-PsA 1. Josef Smolen1, Ennio Lubrano2, Mitsumasa Kishimoto3, Andra R Bălănescu4, Vibeke Strand5, Tianming Gao6, Nancy Vranich6 ...

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials , Rheumatology ...

Effects of upadacitinib on enthesitis in patients with psoriatic arthritis

... psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials ... (SELECT-PsA 1) and NCT03104374 (SELECT-PsA 2). Topic: arthritis ...

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

Methods: This was a post hoc analysis of the double-blind, placebo-controlled SELECT-PsA 1 (also adalimumab-controlled) and SELECT-PsA 2 trials.

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis

METHODS: This was a post hoc analysis of the double-blind, placebo-controlled SELECT-PsA 1 (also adalimumab-controlled) and SELECT-PsA 2 trials.

powerful disease control in psa 2,3 - rinvoq hcp

Disease control with upadacitinib in patients with psoriatic arthritis: a post hoc analysis of the randomized, placebo-controlled SELECT-PsA 1 and 2 phase 3 ...

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate ...

In a post hoc analysis of SELECT-PsA 2, patients also achieved a higher rate of tight disease control (based on Disease Activity in Psoriatic ...

Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients

... hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2). Fabrizio ... SELECT-PsA Clinical trials program 1,2. The objective of this analysis was ...

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis ...

This post hoc analysis of DISCOVER-1 and -2 included 1002 biologic-naïve patients with active PsA from Russia (n = 317) and the rest of the ...

Full article: Efficacy of risankizumab across subgroups in patients ...

... hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials ... This post hoc analysis is not without limitations. The ...

Efficacy of guselkumab on axial involvement in patients with active ...

... psoriatic arthritis in the phase 3 DISCOVER-1 and DISCOVER-2 studies. ... These post-hoc analyses of DISCOVER-1 and DISCOVER-2 focused on the ...

Long-term safety of Ixekizumab in adults with psoriasis, psoriatic ...

... a post-hoc analysis of final safety data from 25 randomized clinical trials ... Studies UNCOVER-1, -2 and -3 had 12-week, randomized ...

Persistent Patient‐Level Effect of Guselkumab at Consecutive 8 ...

As such, post hoc analyses of the 2-year DISCOVER-2 trial of biologic-naïve patients with active PsA were conducted to evaluate individual ...